S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
Flee to Healthcare Stocks if Recession Rears its Head?
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
3 Tasty Dividend Stocks With Value and Above-Average Yields
3 ETFs for the Conservative Investor to Buy and Hold
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
5 NYSE-Listed Emerging Market Stocks For Income Investors
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Disney Denies Rumors of TV Sale, After Stock Jumps on News
Are These Consumer Staples Too Cheap for Investors To Ignore?
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
Flee to Healthcare Stocks if Recession Rears its Head?
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
3 Tasty Dividend Stocks With Value and Above-Average Yields
3 ETFs for the Conservative Investor to Buy and Hold
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
5 NYSE-Listed Emerging Market Stocks For Income Investors
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Disney Denies Rumors of TV Sale, After Stock Jumps on News
Are These Consumer Staples Too Cheap for Investors To Ignore?
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
Flee to Healthcare Stocks if Recession Rears its Head?
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
3 Tasty Dividend Stocks With Value and Above-Average Yields
3 ETFs for the Conservative Investor to Buy and Hold
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
5 NYSE-Listed Emerging Market Stocks For Income Investors
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Disney Denies Rumors of TV Sale, After Stock Jumps on News
Are These Consumer Staples Too Cheap for Investors To Ignore?
S&P 500   4,402.20
DOW   34,440.88
QQQ   364.54
Flee to Healthcare Stocks if Recession Rears its Head?
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
3 Tasty Dividend Stocks With Value and Above-Average Yields
3 ETFs for the Conservative Investor to Buy and Hold
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
Stock market today: World shares track Wall Street's slump after Fed says rates may stay high in '24
5 NYSE-Listed Emerging Market Stocks For Income Investors
His system isolated NVIDIA - Here's His Next Buy. (Ad)
Disney Denies Rumors of TV Sale, After Stock Jumps on News
Are These Consumer Staples Too Cheap for Investors To Ignore?
NYSEAMERICAN:ATNM

Actinium Pharmaceuticals (ATNM) Stock Forecast, Price & News

$6.26
0.00 (0.00%)
(As of 09/20/2023 ET)
Compare
Today's Range
$6.14
$6.43
50-Day Range
$7.12
$14.26
52-Week Range
$5.87
$15.12
Volume
162,459 shs
Average Volume
284,573 shs
Market Capitalization
$169.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.32

Actinium Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
352.4% Upside
$28.32 Price Target
Short Interest
Bearish
7.63% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.05) to ($1.42) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.73 out of 5 stars


ATNM stock logo

About Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Stock

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for bone marrow transplant conditioning; and a Phase I study with a CD19- targeted CAR T-cell therapy with memorial sloan kettering cancer center. The company also offers clinical and preclinical development programs that utilize multiple isotopes, including Actinium-225, Iodine-131, and Lutetium-177 directed at multiple targets in oncology and hematology, including CD45, CD33, HER3, and other. It has collaboration with Astellas Pharma, Inc. to develop theranostics for solid tumor indications; EpicentRx, Inc that focuses on a novel CD47 immunotherapy targeted radiotherapy; and AVEO Oncology that focuses on developing a HER3 targeting ARC for solid tumors. The company is based in New York, New York.

ATNM Price History

ATNM Stock News Headlines

66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
Catalyst Pharmaceuticals
See More Headlines
Receive ATNM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Actinium Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ATNM Company Calendar

Last Earnings
8/14/2023
Today
9/21/2023
Next Earnings (Estimated)
11/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NYSEAMERICAN:ATNM
CIK
N/A
Fax
N/A
Employees
49
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$28.32
High Stock Price Forecast
$50.00
Low Stock Price Forecast
$11.60
Forecasted Upside/Downside
+352.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-33,020,000.00
Pretax Margin
-102,975.55%

Debt

Sales & Book Value

Annual Sales
$1.03 million
Book Value
$2.61 per share

Miscellaneous

Free Float
25,999,000
Market Cap
$169.02 million
Optionable
Optionable
Beta
0.38
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Sandesh C. Seth M.B.A. (Age 59)
    M.S., MBA, Chairman & CEO
    Comp: $1.15M
  • Mr. Steven O'Loughlin BS (Age 37)
    CFO & Corp. Sec.
    Comp: $585k
  • Dr. Paul Diamond Esq.
    Ph.D., VP of Patent & Legal Counsel
  • Dr. David Gould
    Sr. VP of Corp. Devel. & Corp. Affairs
  • Dr. Bernie Cunningham P.M.P.
    Ph.D., Exec. Director of Clinical Supply Chain & Logistics and CMC Project Management
  • Dr. Qing Liang
    VP & Head of Radiation Sciences
  • Dr. Avinash Desai M.D.
    Chief Medical Officer
  • Ms. Jenny Hsieh
    Chief Strategy Officer
  • Ms. Sunitha Lakshminarayanan
    Sr. VP, Head of CMC & Product Devel.
  • Ms. Elaina Haeuber
    VP & Head of Clinical Operations













ATNM Stock - Frequently Asked Questions

Should I buy or sell Actinium Pharmaceuticals stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Actinium Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ATNM shares.
View ATNM analyst ratings
or view top-rated stocks.

What is Actinium Pharmaceuticals' stock price forecast for 2023?

4 brokerages have issued 1-year price targets for Actinium Pharmaceuticals' stock. Their ATNM share price forecasts range from $11.60 to $50.00. On average, they expect the company's stock price to reach $28.32 in the next twelve months. This suggests a possible upside of 352.4% from the stock's current price.
View analysts price targets for ATNM
or view top-rated stocks among Wall Street analysts.

How have ATNM shares performed in 2023?

Actinium Pharmaceuticals' stock was trading at $10.65 on January 1st, 2023. Since then, ATNM stock has decreased by 41.2% and is now trading at $6.26.
View the best growth stocks for 2023 here
.

When is Actinium Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our ATNM earnings forecast
.

How were Actinium Pharmaceuticals' earnings last quarter?

Actinium Pharmaceuticals, Inc. (NYSEAMERICAN:ATNM) issued its quarterly earnings data on Monday, August, 14th. The biotechnology company reported ($0.58) EPS for the quarter, missing analysts' consensus estimates of ($0.50) by $0.08.

When did Actinium Pharmaceuticals' stock split?

Shares of Actinium Pharmaceuticals reverse split before market open on Tuesday, August 11th 2020. The 1-30 reverse split was announced on Monday, August 10th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Monday, August 10th 2020. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Actinium Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Actinium Pharmaceuticals investors own include OHR Pharmaceutical (OHRP), Fitbit (FIT), Global Ship Lease (GSL), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Gran Tierra Energy (GTE), Aeterna Zentaris (AEZS) and Bionano Genomics (BNGO).

What is Actinium Pharmaceuticals' stock symbol?

Actinium Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ATNM."

Who are Actinium Pharmaceuticals' major shareholders?

Actinium Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include BlackRock Inc. (6.60%), Geode Capital Management LLC (2.03%), State Street Corp (1.87%), Northern Trust Corp (0.85%), Bank of New York Mellon Corp (0.45%) and Nuveen Asset Management LLC (0.39%).
View institutional ownership trends
.

How do I buy shares of Actinium Pharmaceuticals?

Shares of ATNM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Actinium Pharmaceuticals' stock price today?

One share of ATNM stock can currently be purchased for approximately $6.26.

How much money does Actinium Pharmaceuticals make?

Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) has a market capitalization of $169.02 million and generates $1.03 million in revenue each year. The biotechnology company earns $-33,020,000.00 in net income (profit) each year or ($1.81) on an earnings per share basis.

How can I contact Actinium Pharmaceuticals?

Actinium Pharmaceuticals' mailing address is 275 Madison Avenue, 7Th Floor, NEW YORK, NY 10016, United States. The official website for the company is www.actiniumpharmaceuticals.com. The biotechnology company can be reached via phone at (646) 677-3870 or via email at investorrelations@actiniumpharma.com.

This page (NYSEAMERICAN:ATNM) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -